]]> What are the challenges to developing more convenient, oral-based biologics? Credit: Shutterstock.
Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.
Over the past few decades, the rise of biologics has been nothing short of meteoric. Between 2010 and 2017, around a quarter of the new molecular entities approved by the US Food and Drug Administration (FDA) fell into this bracket (63 out of a total of 262). That may not sound like a lot, but since biologics are much more expensive than small molecule drugs, they account for most of the worlds top-selling drugs by revenues. They also represent one of the fastest growing categories in pharma.
Unfortunately, biologics have a major downside when it comes to delivery. Unlike small molecule drugs, which can generally be taken orally, biologics are large, complex entities that degrade rapidly in the gastrointestinal tract. Weighing between 200 and 1,000 times the size of a small molecule drug, they almost always need to be delivered via injection or infusion. This is far less convenient than swallowing a pill, not to mention far more costly.
To take diabetes management as an example, most people with diabetes still rely on multiple daily injections. Inhalable insulin has been tried out (as per Exubera in 2006 and Afrezza in 2014) but both suffered with safety concerns and poor sales volume. Oral insulin the holy grail of diabetes treatment has yet to hit the market.
There are dozens of groups around the world intent on creating oral delivery methods. Some focus on modifying the drugs chemical structure to improve their stability in the body. Others focus on the epithelial barrier in the gut if you can make that more permeable, large molecules will be able to pass through more easily.
To give an example of the first approach, researchers at EFPL in Switzerland are working on a method to deliver peptides orally. In 2018, the team developed double bridged peptides a structure with much more stability than a typical amino acid chain. Unfortunately, despite this added stability, most of them still disintegrated in the digestive tract.
Since then, the researchers have found a way to trawl through a peptide library (billions of random peptide sequences, twisted into the double bridged format) to identify the ones that actually are stable. After they have isolated the surviving candidates, they do further tests to find the ones that bind to the disease target.
Its a bit like searching for a needle in a haystack, and this method makes this easy, said Professor Christian Heinis, the lead researcher.
An example of the latter approach comes from Israeli biotech Chiasma. Its Transient Permeability Enhancer (TPE) aims to protect drug molecules from digestive enzymes, as well as triggering the temporary expansion of tight spaces in that gut barrier.
This gives just enough space for the drug molecule to pass into the bloodstream, but not enough space for viruses and bacteria. Last year, the company completed a phase III trial on oral capsules called Mycapssa, which could be used as a maintenance treatment for acromegaly.
There are also a number of oral delivery approaches involving nanoparticles. As the thinking goes: if you incorporate the drug into tiny transporting particles, those particles will be able to protect it from stomach acid, as well as accurately targeting its delivery.
Researchers at Houston Methodist Research Institute in Texas are trialling one such approach, in which a peptide-based drug is chemically linked to fatty acids, and packaged in a nanoparticle. In mouse studies, the animals absorbed almost a quarter of the drug dosage (a lot, considering the typical oral bioavailability for a biologic stands at around 1%).
We know the human body can absorb fatty acids, so we decided to chemically link biological drug molecules to fatty acids to see how well these drugs are absorbed into the gastrointestinal system. It turns out that our transporter approach was effective, saidDr Haifa Shen, Professor of Nanomedicine at Houston Methodist.
Nanotechnology could have many further applications within drug delivery. In particular, it could be used for delivering drugs across the blood-brain barrier, a network of blood vessels that functions a bit like neurological armour. While this barrier protects the brain from harmful chemicals, it also prevents therapeutic agents from getting through.
Researchers at Cedars-Sinai Medical Center in California are working on a new type of nano-immunotherapy, which could deliver cancer drugs directly into brain tumours. Again, they are at an early stage of research, but mouse studies have shown promising results.
Current clinically proven methods of brain cancer immunotherapy do not ensure that therapeutic drugs cross the blood-brain barrier, said Dr Julia Ljubimova, Professor of Neurosurgery and Biomedical Sciences at Cedars-Sinai. Although our findings were not made in humans, they bring us closer to developing a treatment that might effectively attack brain tumours with systematic drug administration.
Another exciting research avenue is microneedles. The promise is clear a minimally invasive, painless technique that could deliver the drug through the skin.
One example is a smart, adhesive insulin-delivery patch, being developed by bioengineers at UCLA. The patch, which is adhesive and resembles a sticking plaster, is pre-loaded with insulin and releases the medicine once blood sugar levels exceed a certain threshold. The technology has been accepted into the FDAs Emerging Technology Program, and human trials could start within the next few years.
US biotech Rani Therapeutics is combining both approaches microneedles and oral biologics delivery with its so-called robotic pill. This capsule, which could be used to deliver a number of biologics, moves through the stomach intact, before reaching the desired location in the gut. Here, it releases biodegradable microneedles, which inject the biologic.
This delivery system is still at an early stage of development, but in preclinical tests it performed as well as a subcutaneous injection. The company also has one human trial to its name a phase I trial for a drug called octreotide, which is normally injected intravenously.
While these research groups, and many others, are seeing promising results in the lab and early trials, it remains to be seen which new delivery methods will become a clinical reality. Given the challenges associated with existing delivery methods, and the seemingly unstoppable rise of biologics, there is everything to play for.
Go here to see the original:
How research groups are tackling the problem of biologic drug delivery - Pharmaceutical Technology
- Is there an alternative to radiation - November 8th, 2009 [November 8th, 2009]
- Taiwan exploring how nanotech affects health - November 8th, 2009 [November 8th, 2009]
- A new way of treating cancer on the way? - November 8th, 2009 [November 8th, 2009]
- Lasers can destroy cancer cells - November 8th, 2009 [November 8th, 2009]
- Fluorescent molecules can be biomarkers - November 8th, 2009 [November 8th, 2009]
- Quick blood tests by using a nanodevice - November 8th, 2009 [November 8th, 2009]
- Where will medicine be 20 years from now - November 8th, 2009 [November 8th, 2009]
- History of nanotechnology - November 8th, 2009 [November 8th, 2009]
- Nanotech and Cancer - November 8th, 2009 [November 8th, 2009]
- Nanotechnology in medicine - November 8th, 2009 [November 8th, 2009]
- How does cancer start - January 25th, 2010 [January 25th, 2010]
- Lung cancer symptoms - January 26th, 2010 [January 26th, 2010]
- Signs of breast cancer - January 27th, 2010 [January 27th, 2010]
- Famous people with cancer - January 29th, 2010 [January 29th, 2010]
- Metastatic renal cancer - January 30th, 2010 [January 30th, 2010]
- What causes skin cancer - January 31st, 2010 [January 31st, 2010]
- How many people die from cancer each year - February 1st, 2010 [February 1st, 2010]
- How much money is spent on cancer research - February 2nd, 2010 [February 2nd, 2010]
- Colon cancer warning signs - February 4th, 2010 [February 4th, 2010]
- Prostate cancer symptoms - February 4th, 2010 [February 4th, 2010]
- Nano-devices that cross blood-brain barrier open door to treatment of cerebral palsy - April 25th, 2012 [April 25th, 2012]
- Nano-devices that cross blood-brain barrier open door to treatment of cerebral palsy, other neurologic disorders - April 25th, 2012 [April 25th, 2012]
- Nanomaterial properties in complement activation: lessons from nanomedicine - Video - May 4th, 2012 [May 4th, 2012]
- OMICS Group :: International Conference and Exhibition on Nanotechnology - May 4th, 2012 [May 4th, 2012]
- Use of Nanotechnology in Medicine [FOX 11-27-2011] - Video - May 4th, 2012 [May 4th, 2012]
- Cancer Nanomedicine - Detection - Video - May 4th, 2012 [May 4th, 2012]
- Cancer Nanomedicine - Video - May 4th, 2012 [May 4th, 2012]
- HBIO Reports First Quarter 2012 Revenue Growth of 8% Over First Quarter 2011 - May 5th, 2012 [May 5th, 2012]
- Nano science, focus of Education Ministry - May 7th, 2012 [May 7th, 2012]
- Drug-resistant Bacteria - Designing Nanoparticles For High Antibiotic Doses - May 7th, 2012 [May 7th, 2012]
- Research and Markets: Global Market for Nano Silver - May 10th, 2012 [May 10th, 2012]
- Cracking study makes nanotech breakthrough - May 10th, 2012 [May 10th, 2012]
- Nanoparticles may pose environmental threat - May 16th, 2012 [May 16th, 2012]
- Global Nanobiotechnology Industry - May 17th, 2012 [May 17th, 2012]
- 'Inability to give back Singur land my biggest regret' - May 20th, 2012 [May 20th, 2012]
- 'KOREA PACK 2012' for Packing process industry to be held at KINTEX - May 23rd, 2012 [May 23rd, 2012]
- New ISO Technical Report Guides Characterization of Nanomaterials in Toxicology - May 29th, 2012 [May 29th, 2012]
- DNA strands create tiniest Smileys - May 30th, 2012 [May 30th, 2012]
- Health and fitness agenda: Evolution Asia Yoga Conference - June 2nd, 2012 [June 2nd, 2012]
- UC Davis work in humanities receives $150,000 in UC-wide grants - June 2nd, 2012 [June 2nd, 2012]
- Computer-designed proteins 'may help fight variety of flu viruses' - June 3rd, 2012 [June 3rd, 2012]
- 'Nano technology' [program can pay off big for IRSC students - June 3rd, 2012 [June 3rd, 2012]
- Computer-designed proteins programmed to disarm variety of flu viruses - June 3rd, 2012 [June 3rd, 2012]
- Jugaad innovators don't plan - they improvise - June 6th, 2012 [June 6th, 2012]
- Health and fitness agenda: World Blood Donor Day - June 9th, 2012 [June 9th, 2012]
- OMICS Group :: Journal of Nanomedicine - June 9th, 2012 [June 9th, 2012]
- Researchers develop a 'time bomb' to fight cardiovascular disease - June 10th, 2012 [June 10th, 2012]
- Nanotechnologists develop a 'time bomb' to fight cardiovascular disease - June 10th, 2012 [June 10th, 2012]
- 'Time bomb' to fight cardiovascular disease developed - June 11th, 2012 [June 11th, 2012]
- Asia's First Graphene Nano-Tech Facility Opens In Singapore - June 13th, 2012 [June 13th, 2012]
- How worms are pioneering remote control medicine - June 13th, 2012 [June 13th, 2012]
- Golden Helix Establishes Direct Presence in Japan - June 13th, 2012 [June 13th, 2012]
- STDs Blocked by Nano Gel, Study Suggests - June 15th, 2012 [June 15th, 2012]
- Real Products, Different Results - June 15th, 2012 [June 15th, 2012]
- The Puridone Program - A Breakthrough for Painkiller Addiction - June 15th, 2012 [June 15th, 2012]
- Six startup medical device firms compete in Memphis for fame and fortune - June 19th, 2012 [June 19th, 2012]
- International Nanomedicine Conference bound for Sydney: July 2-4, 2012 - June 19th, 2012 [June 19th, 2012]
- Taming light with graphene - June 21st, 2012 [June 21st, 2012]
- Today on New Scientist: 25 June 2012 - June 26th, 2012 [June 26th, 2012]
- A step towards the future - July 1st, 2012 [July 1st, 2012]
- Genia Technologies Collaborates with Professors Jingyue Ju at Columbia and George Church at Harvard to Develop a ... - October 4th, 2012 [October 4th, 2012]
- Scientists Invited To Submit Proposals For Biological Research In Space - October 4th, 2012 [October 4th, 2012]
- Research and Markets: Micro-Nano Technology XIII from the 13th Annual Conference of Chinese Society of Micro-Nano ... - October 6th, 2012 [October 6th, 2012]
- $80M research facility to open at UMass Lowell - October 6th, 2012 [October 6th, 2012]
- Nano-revolution in drugs delivery - October 8th, 2012 [October 8th, 2012]
- SENAI/SESI of Sao Paulo Selects NanoProfessor as Foundation for "Nanomundo" Nanotechnology Education Initiative - October 8th, 2012 [October 8th, 2012]
- Delivering an integral approach to emotional and mental health - October 9th, 2012 [October 9th, 2012]
- NanoGuardian's On-Dose NanoEncryption Brand Protection Technology to Be Presented at AAPS Annual Meeting - October 11th, 2012 [October 11th, 2012]
- Il Nano Mondo del professor Ennio Tasciotti - Video - October 30th, 2012 [October 30th, 2012]
- Deakin University - Practical Science - Nano medicine - Video - October 30th, 2012 [October 30th, 2012]
- 2012 Deakin University 3 Minute Thesis Finalist - Jarrad Altimari - Video - October 30th, 2012 [October 30th, 2012]
- Nano Medicine from "Development of Nanotechnology in Hong Kong" - Video - October 30th, 2012 [October 30th, 2012]
- NANO Medicine 1 3 xvid - Video - October 30th, 2012 [October 30th, 2012]
- Nanolääke // Nano medicine - Video - October 30th, 2012 [October 30th, 2012]
- NANO Medicine (1-3) - Video - October 30th, 2012 [October 30th, 2012]
- Jefferson County, Colorado's Bioscience Industry - Video - October 30th, 2012 [October 30th, 2012]
- NanoMission - Nanomedicine NanoBot - Video - October 30th, 2012 [October 30th, 2012]
- Study aims to unlock mysteries of autism - November 20th, 2012 [November 20th, 2012]
- Catherine Griwkowsky - November 22nd, 2012 [November 22nd, 2012]
- Kulkarni to be feted at Bangalore Nano 2012 - November 26th, 2012 [November 26th, 2012]